Serum albumin: its relationship to marrow and renal toxicity from platinum-based combination chemotherapy.
One hundred and three patients treated with CAP chemotherapy were evaluated to determine the relationship between low prechemotherapy serum albumin (less than 3 g/dl) and low WBC nadir (less than 2000 cells/mm3). Additionally, the relationship of serum albumin to renal toxicity (delta serum creatinine) was examined. Low prechemotherapy serum albumin appears to be a marker for advanced disease, but does not appear to predict marrow or renal toxicity.
Belinson
J L
JL
Department of Obstetrics and Gynecology, University of Vermont, Burlington 05401.
Jarrell
M A
MA
McClure
M
M
Kulig
P M
PM
Badger
G J
GJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001855:Bone Marrow Diseases / Q000097:blood / Q000139:chemically induced*; D002945:Cisplatin / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced*; D007958:Leukocyte Count / Q000187:drug effects; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012709:Serum Albumin / Q000378:metabolism*; D015996:Survival Rate
D012709:Serum Albumin; D004317:Doxorubicin; D003520:Cyclophosphamide; D003404:Creatinine; D002945:Cisplatin